Kerecis has initially chosen to address two high growth medical device market segments: the biologic chronic wound treatment industry, worth USD 600 million with 26% annual growth and the hernia-repair industry worth USD 1 billion with growth rates in excess of 20%.

Kerecis’ technology addresses the large unmet need of the double-digit growth biologics segment of the chronic wounds and hernia repair markets, represented by our pipeline. It offers advantages over existing human and porcine-derived products, including improved manufacturing economics, lower risk of disease transfer, and the absence of cultural and religious constraints on usage, with equivalent or better clinical performance:

KEY TECHNICAL ADVANTAGES

• Kosher / Halal compatible – reduces cultural or religious barriers to clinician/patient acceptance
• Easier to use, with larger, thicker sheets (no need for multi-layer grafts)
• Non allergenic and bio-compatible
• Lower risk of disease transfer
• Enhanced cell proliferation and vascularization
• Improved infection control
• Adjustable rate of absorption into the surrounding tissue

When the MariGen™ Omega3 Extra Cellular Matrix is inserted into or onto damaged tissue the material acts as a scaffold and is revascularized and repopulated by the host’s cells. The natural lipids in the matrix reduce inflammatory reactions. The material is ultimately converted into living tissue.